CN110317211A - Substituted polycyclic pyridone compound and prodrug thereof - Google Patents
Substituted polycyclic pyridone compound and prodrug thereof Download PDFInfo
- Publication number
- CN110317211A CN110317211A CN201910675084.1A CN201910675084A CN110317211A CN 110317211 A CN110317211 A CN 110317211A CN 201910675084 A CN201910675084 A CN 201910675084A CN 110317211 A CN110317211 A CN 110317211A
- Authority
- CN
- China
- Prior art keywords
- compound
- compounds
- deuterium
- hydrogen
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a deuterium-substituted polycyclic pyridone compound, a prodrug thereof, a composition containing the compound and application of the composition. The compounds and compositions of the present invention exhibit cap-dependent endonuclease inhibitory activity and have superior pharmacokinetic properties.
Description
Technical field
The present invention relates to a kind of substituted polycyclic pyridinone compounds and its prodrug and include the composition of the compound
And application thereof.More particularly it relates to (((12aR) -12- (fluoro- 6,11- bis- of (11S) -7,8- bis- that certain deuteriums replace
Diphenyl hydrogen simultaneously (B, E) thiepin -11- base) -6,8- dioxo -3,4,6,8,12,12a- hexahydro -1H- (1,4) oxazines (3,4-
C) pyrido (2,1-F) (1,2,4) triazine -7- base) oxygroup) methyl carbonic acid methyl esters and its female medicine, the compound that these deuteriums replace
And combinations thereof show cap dependence endonuclease (Cap-dependent endonuclease) inhibitory activity, and these
The compound that deuterium replaces has more excellent pharmacokinetic property.
Background technique
It is anxious as caused by the infection of influenza virus that influenza, which is referred to as influenza (influenza or flu),
Property respiratory infectious disease, has become the highest viral infection disease of lethality.The old man of over-65s, 2 years old youngster below
Virgin and crowd with chronic respiratory disease and cardiovascular disease is easier that influenza complications occur, therefore is the high-risk of influenza
Crowd.In 20th century, there are extensive flu outbreak three times, spanish influenza in 1918, nineteen fifty-seven Asia influenza and nineteen sixty-eight perfume
Port influenza.Wherein, spanish influenza (H1N1) is destructive, and death toll has been more than the World War I, has infected generation
The population on boundary 30% causes at least 20,000,000 people death.Other flu outbreaks twice are H2N2 and H3N2 type influenza disease respectively
Caused by poison, although scale is smaller, up to a hundred people's death is also resulted in.The one plant of novel Influenza A H1N1 occurred in 2009
Virus causes the first time flu outbreak of 21 century, and research finds that the gene of this virus contains the mankind, pig and birds
It is a kind of recombinant virus etc. the gene order of a variety of influenza viruses.In short several months, which spreads to rapidly complete
Ball causes great fear.The World Health Organization will guard against by three-level, repeatedly be promoted, until being highest six grades.
Influenza virus is divided into first, second, third (also referred to as A, B, C) according to the difference of nucleoprotein and stromatin antigenic characteristic
Three types.The host range of influenza A virus is most wide, can infect people, pig, horse and birds, and pathogenicity is strong, Neng Gouyin
World's flu outbreak is played, it is maximum to the harm of the mankind;Influenza B virus main infection people and pig, pathogenecity is lower, energy
Influenza is caused locally to break out;Influenza virus C only infects the crowd of infant and hypoimmunity, seldom causes prevalence, harm
It is relatively small.
Medicine is emitted as influenza, it is well known mainly to have: (1) amantadine (Amantadine) and Rimantadine
It (Rimantadine) is the two kinds of anti-influenza virus medicaments relatively to early go public, the main M2 ion channel for passing through blocking virus, suppression
Virus uncoating processed and play antivirus action.(2) Oseltamivir phosphate (Oseltamivir Phosphate, trade name: Tamiflu
(Tamiflu), Roche development), (Zanamivir, trade name: Yi Lewei (Relenza), GlaxoSmithKline PLC is ground zanamivir
System), it is neuraminidase inhibitor, curative effect with higher and preferable safety and tolerance, are the head of current anti influenza
Select drug.However, there is the problem of appearance of endurance strain, side effect, and there are pathogenicity or the higher novel prevalence of lethal
Sexuality emits virosphere and the misgivings such as is very popular, and the influenza therefore it is desirable to develop new mechanism out emits medicine.
About the cap dependence endonuclease as the enzyme for being originated from influenza virus, since it is for virus multiplication
For be necessary, and the virus-specific enzymatic activity not having with host, so think the cap dependence endonuclease
Enzyme is suitable for the object that influenza emits medicine.The cap dependence restriction endonuclease of influenza virus is before generating with host mRNA
Body be substrate and include cap structure 9~13 bases (base of cap structure is simultaneously not included in above-mentioned base quantity) piece
The endonuclease activity of section.The segment is functioned as the introduction of viral RNA polymerase, is used for encoded viral proteins
MRNA synthesis.I.e., it is believed that inhibit the substance of cap dependence endonuclease by inhibiting the synthesis of virus mRNA to inhibit
The synthesis of virus protein, as a result inhibits virus multiplication.
Baloxavir Marboxil (also known as S-033188, chemical name are (((12aR) -12- ((11S) -7,8- bis-
Fluoro- 6,11- dihydro-dibenzo (B, E) thiepin -11- base) -6,8- dioxo -3,4,6,8,12,12a- hexahydro -1H- (1,4)
Oxazines (3,4-C) pyrido (2,1-F) (1,2,4) triazine -7- base) oxygroup) methyl carbonic acid methyl esters, have following structure) be
Japanese Shionogi Seiyaku Kabushiki Kaisha (Shionogl&Co., Ltd) exploitation a pioneering (first-in-class), single dose are real
The property tested oral drugs, it is intended to inhibit cap dependence endonuclease in influenza virus, play the role of suppressing virus replication.2016
Years 2 months, the development rights in area other than Japan and TaiWan, China were assigned to Roche by the wild justice of salt.Baloxavir Marboxil is
In on 2 23rd, 2018 in Japan by accelerating examination & approval and successfully listing A type for treating adult and child patient and B-mode
Influenza, trade name Xofluza.In June, 2018, Roche announce that U.S. FDA has accepted the new drug of Baloxavir Marboxil
Apply and be granted by preferential examination qualification, it is contemplated that examination will be made on December 24th, 2018 and determined.Clinical test shows
Baloxavir Marboxil only needs single dose (40 or 80mg every time takes 1 day once a day) to be administered, and just can be reduced influenza
The duration of symptom, and virus shedding is substantially reduced in one day, compared to Oseltamivir, (each 75mg, one day is secondary, takes
5 days) there is more powerful Anti-viral Treatment, first day after receiving treatment, 50% or more patient (including children) is in vivo
Virus titer drop to detection limit hereinafter, in addition to this, it is also highly effective to swin flu (H5N1 or H7N9).
Known poor absorption, distribution, metabolism and/or excretion (ADME) property are to lead to many drug candidate clinical tests
The main reason for failure.The many drugs currently listed are also due to poor ADME property limits their application range.Medicine
The tachymetabolism of object will lead to many drugs that can efficiently treat disease originally fallen from internal metabolite clearance due to too fast and
It is difficult to patent medicine.Frequently or high dose medication is although it is possible to solve the problems, such as that drug is quickly removed, but this method can be brought such as
The problems such as side effect caused by patient dependence is poor, high dose is taken medicine and treatment cost rise.In addition, the drug of tachymetabolism
Patient may be made to be exposed in undesirable toxicity or reactive metabolin.
Although Baloxavir Marboxil can effectively treat influenza, there are still serious clinics in the field
Unmet demand is found to have with good oral administration biaavailability and has the new compound of druggability still to have challenge
The work of property.Therefore, this field, which still needs to exploitation, has inhibition cap dependence endonuclease activity and/or preferably medicine for power
Compound, the present invention provides such compounds.
Summary of the invention
Against the above technical problems, the invention discloses a kind of polycyclic Pyridione derivatives that novel deuterium replaces and its
Prodrug and the composition comprising the compound and application thereof have and preferably inhibit cap dependence endonuclease activity, special
It is not that there is preferably pharmacokinetics performance and/or oral administration biaavailability.
In this regard, the invention adopts the following technical scheme:
The first aspect of the present invention provides formula (I) compound:
Wherein,
P is selected from H or-C (R11R12)OC(O)OC(R13R14R15);
Y1、Y2、Y3、Y4、Y5、Y6、Y7And Y8It is each independently selected from hydrogen or deuterium;
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14And R15It is each independently selected from hydrogen or deuterium;
Additional conditions are that above compound at least contains a D-atom;
Or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvent chemical combination
Object.
On the other hand, the present invention provides contain the compounds of this invention or its tautomer, stereoisomer, preceding
The pharmaceutical composition of medicine, pharmaceutically acceptable salt, crystal form, hydrate or solvated compounds and pharmaceutically acceptable excipient
Object.In a particular embodiment, the compounds of this invention or its tautomer, stereoisomer, prodrug, pharmaceutically acceptable
Salt, crystal form, hydrate or solvated compounds are provided in described pharmaceutical composition with effective quantity.In a particular embodiment, originally
Invention compound or its tautomer, stereoisomer, prodrug, pharmaceutically acceptable salt, crystal form, hydrate or solvation
Object is closed to provide with therapeutically effective amount.In a particular embodiment, the compounds of this invention or its tautomer, stereoisomer,
Prodrug, pharmaceutically acceptable salt, crystal form, hydrate or solvated compounds are provided with prevention effective dose.
On the other hand, the present invention provides a kind of pharmaceutical composition as described above or its tautomer, solid are different
The preparation method of structure body, prodrug, pharmaceutically acceptable salt, crystal form, hydrate or solvated compounds, comprising the following steps: will
Pharmaceutically acceptable excipient and the compounds of this invention or its pharmaceutically acceptable salt, crystal form, hydrate or solvent chemical combination
Object is mixed, to form pharmaceutical composition.
On the other hand, the present invention provides a kind of pharmaceutical compositions, and it includes the compounds of this invention or its tautomerisms
Body, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds inhibit with neural amino acid enzyme
Agent, RNA Dependent RNA polymerase inhibitors, M2 protein inhibitor, PB2Cap binding inhibitors, anti-HA antibody or immune
Make the combination of medication.
On the other hand, the present invention provides a kind of the compounds of this invention or its tautomers, stereoisomer, preceding
Medicine, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds be used to prepare treatment and prevention with by with cap according to
Rely the purposes in the drug of disease caused by the virus of property endonuclease.
On the other hand, the invention further relates to provide one kind in subject treat and/or prevent with by being relied on cap
The method of disease caused by the virus of property endonuclease, this method includes the present invention to snibject's therapeutically effective amount
Compound or its pharmaceutically acceptable salt, crystal form, hydrate or solvated compounds or pharmaceutical composition.In specific embodiment
In, it is oral, subcutaneous, intravenously or intramuscularly interior that the compound is administered.In a particular embodiment, chemical combination described in long term administration
Object.
The present invention further provides a kind of cure of influenza infectious disease using prodrug compound or preventive treatment,
And the above compound of effect is emitted with influenza.The present invention further provides a kind of female chemical combination of prodrug compound
Object.The parent compound system emits agent or the intermediate of the prodrug compound as influenza.
The compound of the present invention has the activity for inhibiting cap dependence endonuclease.Preferred compound is prodrug,
Since it becomes the parent compound with the inhibitory activity to cap dependence endonuclease, conduct in vivo upon administration
The therapeutic agent and/or prophylactic of influenza infectious disease and it is useful.
By subsequent specific embodiment, embodiment and claim, other objects and advantages of the present invention will be for this
Field technical staff is apparent.
Definition
Herein, unless otherwise instructed, " deuterated " refers to one or more hydrogen in compound or group replaced deuterium;Deuterium
In generation, can be a substitution, two replace, polysubstituted or full substitution.Term " one or more deuterated " and " one or many deuterated "
It is used interchangeably.
Herein, unless otherwise instructed, " non-deuterated compound " refers to ratio containing D-atom not higher than the same position of natural deuterium
The compound of cellulose content (0.015%).
Term " pharmaceutically acceptable salt " refers to, in reliable medical judgment scope, is suitble to and people and lower animal
Tissue contact without excessive toxicity, irritation, allergy etc., and match with reasonable benefit/hazard ratio
Those salt.Pharmaceutically acceptable salt is well known in the art.For example, Berge et al. is in J.Pharmaceutical
The pharmaceutically acceptable salt being described in detail in Sciences (1977) 66:1-19.The compounds of this invention it is pharmaceutically acceptable
Salt include the salt derived from suitable inorganic and organic bronsted lowry acids and bases bronsted lowry.
The compounds of this invention can be amorphous or crystal form.In addition, the compounds of this invention can be with one or more
Crystal form exists.Therefore, the present invention includes all amorphous or crystal form of the compounds of this invention within its scope.Term
" crystal form " refers to the different arrangement modes of chemicals molecule, normally behave as medicine material in the solid state there are shapes
Formula.A kind of drug can exist with a variety of crystal-form substances states, and the different crystal forms of same drug, dissolution and absorption in vivo can
Can be different, thus can dissolution to preparation and release have an impact.
Term " crystal form " refers to the different arrangement modes of chemicals molecule, normally behaves as medicine material in solid state
Under existence form.A kind of drug can exist with a variety of crystal-form substances states, the different crystal forms of same drug, in vivo molten
Solution and absorb may be different, thus can dissolution to preparation and release have an impact.
As used herein, term " subject " includes but is not limited to: people is (that is, the sex of any age group, example
Such as, pediatric subject (for example, baby, children and adolescents) or Adult human subjects (for example, young adult, the adult in middle age or
Old adult)) and/or inhuman animal, for example, mammal, for example, primate (for example, machin, rhesus macaque),
Ox, pig, horse, sheep, goat, rodent, cat and/or dog.In some embodiments, subject is people.In other realities
It applies in scheme, subject is non-human animal.
" disease ", " obstacle " and " illness " interchangeably in this specification uses.
Unless otherwise noted, terms used herein " treatment " include subject with disease specific, obstacle or disease
The effect occurred when disease, it reduces disease, the severity of obstruction and illness, or postpones or slow down disease, obstruction and illness
Development (" therapeutic treatment "), further include that subject starts with the effect occurred before disease specific, obstacle or disease
(" prophylactic treatment ").
In general, " effective quantity " of compound refers to the quantity for being enough to cause target organism to react.As the common skill in this field
As art personnel understand, the effective quantity of the compounds of this invention can change according to following factors: for example, biology mesh
The age health condition and symptom of mark, the pharmacokinetics of compound, the disease treated, mode of administration and subject.Have
Effect amount includes treatment and prevention property therapeutically effective amount.
Unless otherwise noted, " therapeutically effective amount " of compound used herein is in treatment disease, obstacle or disease
It is enough to provide the helpful quantity for the treatment of during disease, or prolongs one or more symptoms related with disease, obstruction and illness
Late or minimize.The therapeutically effective amount of compound refer to be used alone or with other therapies associated with therapeutic agent quantity, it
Treatment benefit is provided during treatment disease, obstruction and illness.Term " therapeutically effective amount " may include improve overall therapeutic,
Reduce or avoid disease or illness symptom the cause of disease or enhance other therapeutic agents therapeutic efficacy quantity.
Unless otherwise noted, " prevention effective dose " of compound used herein be enough to prevent disease, obstacle or
The quantity of illness, or be enough to prevent the quantity of one or more symptoms related with disease, obstruction and illness, or prevent disease, barrier
Hinder or illness recurrence quantity.The prevention effective dose of compound refer to be used alone or with other medicaments associated with therapeutic agent number
Amount, it provides prevention benefit during preventing disease, obstruction and illness.Term " prevention effective dose " may include improving always
The quantity of body prevention, or the quantity of the other prevention efficiency for preventing medicaments of enhancing.
" combination " and relational language, which refer to, is administered either simultaneously or sequentially therapeutic agent of the invention.For example, the compounds of this invention
The unit dosage forms that can be separated with another therapeutic agent are administered either simultaneously or sequentially, or are in single unit dose together with another therapeutic agent
Type is administered simultaneously.
Specific embodiment
Compound
So-called " prodrug " in this specification refers to formula (II) compound represented or its pharmacy in reaction equation below
Upper acceptable salt, expression is under physiological condition in vivo by by drug metabolic enzyme, hydrolase, gastric acid, intestinal bacterium
It is converted into formula (III) compound represented Deng caused decomposition reaction, to show cap dependence endonuclease
(CEN) compound of inhibitory activity, and/or CPE inhibitory effect.
(in formula, each symbol is identical as above-mentioned implication)
Prodrug shown in the formula (II) more preferably indicates: bioavilability and/or AUC (the blood medicine when vivo medicine-feeding
The area that concentration curve surrounds time shaft) and/or Cmax(the blood concentration peak occurred after administration) is compared with formula (III) institute
The compound that the compound shown is improved.
Therefore, the prodrug efficiently absorbed in stomach and/or intestines etc. after being administered to living body (for example, oral administration) to
In vivo, it is converted into formula (III) compound represented thereafter, therefore preferably shows compared with compound shown in formula (III) more
High treatment and/or preventive effect.
The present invention provides formula (I) compound or its tautomer, stereoisomer, prodrug, crystal form, can pharmaceutically connect
Salt, hydrate or the solvated compounds received:
Wherein,
P is selected from H or-C (R11R12)OC(O)OC(R13R14R15);
Y1、Y2、Y3、Y4、Y5、Y6、Y7And Y8It is each independently selected from hydrogen or deuterium;
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14And R15It is each independently selected from hydrogen or deuterium;
Additional conditions are that above compound at least contains a D-atom.
As the preferred embodiments of the invention, it is same that deuterium isotopic content of the deuterium in deuterated position is at least greater than natural deuterium
Position cellulose content 0.015%, is preferably greater than 30%, even more preferably greater than 50%, even more preferably greater than 75%, even more preferably greater than 95%,
Even more preferably greater than 99%.
Specifically, Y in the present invention1、Y2、Y3、Y4、Y5、Y6、Y7、Y8、R1、R2、R3、R4、R5、R6、R7、 R8、R9、R10、
R11、R12、R13、R14And R15, deuterium isotopic content is at least 5%, even more preferably greater than 10% in each deuterated position, even more preferably greater than
15%, even more preferably greater than 20%, even more preferably greater than 15%, even more preferably greater than 25%, even more preferably greater than 30%, even more preferably greater than
35%, even more preferably greater than 40%, even more preferably greater than 45%, even more preferably greater than 50%, even more preferably greater than 55%, even more preferably greater than
60%, even more preferably greater than 65%, even more preferably greater than 70%, even more preferably greater than 75%, even more preferably greater than 80%, even more preferably greater than
85%, even more preferably greater than 90%, even more preferably greater than 95%, even more preferably greater than 99%.
As the preferred embodiments of the invention, at least contains a D-atom in the compound of formula (I), more preferably contain
Two D-atoms, more preferably containing there are three D-atom, more preferably containing there are four D-atoms, more preferably containing there are five D-atoms, more
The D-atom containing there are six goodly, more preferably contains seven D-atoms, more preferably contains eight D-atoms, more preferably contains nine deuteriums
Atom more preferably contains ten D-atoms, more preferably contains 11 D-atoms, more preferably contains 12 D-atoms, more preferably
Ground contains 13 D-atoms, more preferably contains 14 D-atoms, more preferably contains 15 D-atoms, more preferably contains ten
Six D-atoms more preferably contain 17 D-atoms, more preferably contain 18 D-atoms, more preferably contain 19 deuterium originals
Son more preferably contains 20 D-atoms, more preferably contains 21 D-atoms, more preferably contains 22 D-atoms,
More preferably contain 23 D-atoms.
In a particular embodiment, " Y1、Y2、Y3、Y4、Y5、Y6、Y7And Y8It is each independently selected from hydrogen or deuterium " it include Y1Choosing
From hydrogen or deuterium, Y2Selected from hydrogen or deuterium, Y3Selected from hydrogen or deuterium, and so on, until Y8Technical solution selected from hydrogen or deuterium.More specifically
Ground, including Y1For hydrogen or Y1For deuterium, Y2For hydrogen or Y2For deuterium, Y3For hydrogen or Y3For deuterium, and so on, until Y8For hydrogen or Y8For deuterium
Technical solution.
In another embodiment, " R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14And R15Respectively
From independently selected from hydrogen or deuterium " it include R1Selected from hydrogen or deuterium, R2Selected from hydrogen or deuterium, R3Selected from hydrogen or deuterium, and so on, until R15
Technical solution selected from hydrogen or deuterium.More specifically, including R1For hydrogen or R1For deuterium, R2For hydrogen or R2For deuterium, R3For hydrogen or R3For deuterium,
And so on, until R15For hydrogen or R15For the technical solution of deuterium.
It is preferably carried out in scheme at one, the present invention relates to a kind of compound of formula (I) or its tautomer, stands
Body isomers, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, and R1-R15As defined above, additional conditions are that the compound at least contains one
D-atom.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, and R1-R15As defined above, additional conditions are R7-R15At least one of
It is deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1And R2For hydrogen, and R3-R15It is each independently selected from hydrogen or deuterium, additional strip
Part is that the compound at least contains a D-atom.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1And R2For hydrogen, and R3-R15It is each independently selected from hydrogen or deuterium, additional strip
Part is R7-R15At least one of be deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, and R3、R7-R15Be each independently selected from hydrogen or
Deuterium, additional conditions are that the compound at least contains a D-atom.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, and R3、R7-R15Be each independently selected from hydrogen or
Deuterium, additional conditions are R7-R15At least one of be deuterium.
In another more preferably embodiment, R7-R10It is identical.
In another more preferably embodiment, R7-R10It is deuterium.
In another more preferably embodiment, R7-R10It is hydrogen.
In another more preferably embodiment, R11-R12It is identical.
In another more preferably embodiment, R11-R12It is deuterium.
In another more preferably embodiment, R11-R12It is hydrogen.
In another more preferably embodiment, R13-R15It is identical.
In another more preferably embodiment, R13-R15It is deuterium.
In another more preferably embodiment, R13-R15It is hydrogen.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3For deuterium, and R7-R15It is each independently selected from
Hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3For deuterium, and R7-R15It is each independently selected from
Hydrogen or deuterium, additional conditions are R7-R15At least one of be deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3For deuterium, and R7-R15Be each independently selected from hydrogen or
Deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3For deuterium, and R7-R15Be each independently selected from hydrogen or
Deuterium, additional conditions are R7-R15At least one of be deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R7-R10For deuterium, and R3、R11-R15It is respectively independent
Ground is selected from hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R7-R10For deuterium, and R3、R11-R15It is each independently selected from
Hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3And R7-R10For deuterium, and R11-R15Respectively solely
On the spot it is selected from hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3And R7-R10For deuterium, and R11-R15It selects each independently
From hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R13-R15For deuterium, and R3、R7-R12It is respectively independent
Ground is selected from hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3And R13-R15For deuterium, and R7-R12Respectively solely
On the spot it is selected from hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R13-R15For deuterium, and R3、R7-R12It is each independently selected from
Hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3And R13-R15For deuterium, and R7-R12It selects each independently
From hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R7-R10And R13-R15For deuterium, and R3And R11-
R12It is each independently selected from hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R7-R10And R13-R15For deuterium, and R3And R11-R12Respectively
Independently selected from hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from H or-C
(R11R12)OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3、R7-R10And R13-R15For deuterium, and R11-
R12It is each independently selected from hydrogen or deuterium.
Be preferably carried out in scheme at another, the present invention relates to a kind of compound of formula (I) or its tautomer,
Stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds, wherein P is selected from-C (R11R12)
OC(O)OC(R13R14R15), Y1-Y8For hydrogen, R1-R2And R4-R6For hydrogen, R3、R7-R10And R13-R15For deuterium, and R11-R12Respectively solely
On the spot it is selected from hydrogen or deuterium.
As the preferred embodiments of the invention, the compound is following any structure or its is pharmaceutically acceptable
Salt, but it is not limited to having structure:
The compounds of this invention may include one or more asymmetric centers, and therefore may exist multiple stereoisomers shape
Formula, for example, enantiomter and/or diastereomeric form.For example, the compounds of this invention can be individual enantiomerism
Body, diastereoisomer or geometric isomer (such as cis and trans isomer), or can be the mixture of stereoisomer
Form, the mixture including raceme mixture and rich in one or more stereoisomers.Isomers can pass through ability
Method known to field technique personnel is separated from mixture, which comprises chiral high pressure liquid chromatography (HPLC) and
The formation and crystallization of chiral salt;Or preferred isomers can be prepared by asymmetric syntheses.
It will be understood by those skilled in the art that organic compound can form compound with solvent, occur in the solvent
Reaction is precipitated or is crystallized out from the solvent.These compounds are known as " solvate ".When solvent is water, compound claims
For " hydrate ".Present invention encompasses all solvates of the compounds of this invention.
Term " solvate " refers to the compound or its salt combined with solvent usually formed by solvolysis reaction
Form.This physical association may include hydrogen bonding.Conventional solvents include including water, methanol, ethyl alcohol, acetic acid, DMSO, THF,
Ether etc..Compound as described herein can be prepared into, for example, crystal form, and can be completely solvated.Suitable solvate includes
Pharmaceutically acceptable solvate and further comprise stoichiometry solvate and non-stoichiometric solvate.?
Under some cases, the solvate will be separated, for example, when in the lattice of one or more solvent molecules incorporation crystalline solid
When." solvate " includes the solvate and separable solvate of solution state.Representative solvate includes water
Close object, ethanolates and methanol solvate.
Term " hydrate " refers to the compound combined with water.In general, including the moisture in the hydrate of compound
The ratio of the compound molecule number determines in subnumber and the hydrate.Therefore, such as general formula R x can be used in the hydrate of compound
H2O is represented, and wherein R is the number that the compound and x are greater than 0.Given compound can form over a kind of hydrate type, packet
It includes, for example, (x is greater than 0 and the number less than 1, for example, semihydrate (R for monohydrate (x 1), rudimentary hydrate
0.5H2O)) and polyhydrate (x is number greater than 1, for example, dihydrate (R2H2) and hexahydrate (R6H O2O))。
The compounds of this invention can be amorphous or crystal form (polymorphic).In addition, the compounds of this invention can be with one
Kind or a variety of crystal forms exist.Therefore, the present invention includes all amorphous of the compounds of this invention or crystallization within its scope
Form.Term " polymorph " refers to crystal form (or its salt, hydrate or the solvent of the compound of particular crystal stacked arrangement
Close object).All polymorphs element composition having the same.Different crystal forms usually has different X-ray diffractions
Figure, infrared spectroscopy, fusing point, density, hardness, crystal shape, photoelectric property, stability and solubility.Recrystallization solvent, crystallization speed
Rate, storage temperature and other factors can lead to a kind of crystal form and are dominant.The various polymorphs of compound can be in different items
Pass through crystallization preparation under part.
The invention also includes the compound of isotope labelling, it is those of described but one or more that they are equal to formula (I)
Atom is replaced by the atom that atomic mass or mass number are different from the common atomic mass or mass number of nature.It can introduce
The example of isotope in the compounds of this invention includes the isotope of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine, respectively for example2H、3H、13C、11C、14C、15N、18O、17O、31P、32P、35S、18F and36Cl.It is other same containing above-mentioned isotope and/or other atoms
The compounds of this invention, its pro-drug and the compound of position element or the pharmaceutically acceptable salt of the pro-drug all belong to
In the scope of the present invention.The compounds of this invention of certain isotope labellings, such as introducing radioactive isotope (such as3H and14C)
Those of can be used for drug and/or substrate tissue measure of spread.Tritium, i.e.3H and carbon-14, i.e.14C isotope be it is particularly preferred,
Because they are easy preparation and detection.In turn, replaced by heavier isotope, such as deuterium, i.e.2H, since metabolic stability is higher
Benefit in treatment can be provided, such as extend Half-life in vivo or reduce volume requirements, thus may be in some cases
Preferably.The formula (I) compound and its pro-drug of the present invention of isotope labelling can generally be prepared, and carry out following streams
When technique disclosed in journey and/or embodiment and preparation example, heterotope is replaced with the reagent for the isotope labelling being easy to get
The reagent of label.
Pharmaceutical composition, preparation and kit
On the other hand, the present invention provides pharmaceutical compositions, and it includes the compounds of this invention (also known as " active groups
Point ") and pharmaceutically acceptable excipient.In some embodiments, described pharmaceutical composition includes a effective amount of active group
Point.In some embodiments, described pharmaceutical composition includes the active component of therapeutically effective amount.In some embodiments,
Described pharmaceutical composition includes the active component of prevention effective dose.
Refer to the pharmacology that will not destroy the compound prepared together for pharmaceutically acceptable excipient of the invention
Active non-toxic carriers, adjuvant or mediator.It can be used for pharmaceutically acceptable carrier, adjuvant or the matchmaker in the present composition
Agent includes but is not limited to, ion-exchanger, aluminium oxide, aluminum stearate, lecithin, haemocyanin (such as human serum albumin),
Buffer substance (such as phosphate), glycine, sorbic acid, potassium sorbate, the partial glyceride mixture of saturated vegetable fatty acid, water,
Salt or electrolyte (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, silica gel, magnesium trisilicate, poly- second
Alkene pyrrolidone, the substance based on cellulose, polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxy
Propylene-block polymer, polyethylene glycol and lanolin.
The invention also includes kit (for example, drug packages).Provided kit may include the compounds of this invention,
Other therapeutic agents, and containing the compounds of this invention, other therapeutic agents the first and second containers (for example, bottle, ampoule bottle,
Bottle, syringe and/or dispersible packaging or other suitable containers).In some embodiments, the kit provided can be with
Include optionally third container, contains the pharmaceutical excipient for dilute or suspend the compounds of this invention and/or other therapeutic agents.
In some embodiments, the compounds of this invention in the first container and second container is provided and other therapeutic agents combine to be formed
One unit dosage forms.
Pharmaceutical composition provided by the invention can be administered by many approach, including but not limited to: oral administration, stomach
External administration, inhalation, local administration, rectally, nasal-cavity administration, oral administration, vagina administration, by implant administration or
Other administration modes.For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular
Administration, intra-articular administration, intraarterial delivery, synovial membrane intracavitary administration, administration in breastbone, administration in meninges, intralesional administration,
Injection or infusion techn with encephalic.
In general, giving a effective amount of compound provided in this article.According to related situation, including treated illness, choosing
The administration route selected, the compound actually given, age, weight and the response of individual patient, patient symptom severity, etc.
Deng can determine the amount for the compound actually given by doctor.
When for when preventing illness of the present invention, giving in the subject this paper institute formed among the illness danger
The compound of offer will be typically based on the suggestion of doctor and be administered under doctor's supervision, and dosage level is as described above.In formation
Subject among the danger of specific illness generally includes the subject with the family history of the illness, or passes through heredity examination
It tests or screens and determine subject especially those of sensitive to the formation illness.
Various medications can be used, further deliver pharmaceutical composition of the invention.For example, in some embodiments
In, it can be with inject administration pharmaceutical composition, for example, in order to improve the concentration of compound in blood quickly to effective level.
Bolus dose depends on the target systemic levels of active component, for example, intramuscular or subcutaneous bolus dose keeps active component slow
On The Drug Release, and being directly delivered to the injecting of vein (for example, by IV intravenous drip) can more rapidly deliver, so that active
The concentration of component in blood is quickly increased to effective level.In other embodiments, it can be given in the form of continuous infusion
Pharmaceutical composition, for example, by IV intravenous drip, to provide the active component of Css in subject's body.In addition,
In other embodiments, the pharmaceutical composition of bolus dose can be given first, then continuous infusion.
Orally administered composition can be using bulk liquids solution or suspension or bulk powder form.However, more generally, in order to
Convenient for the administration of accurately dosage, the composition is provided in a unit.Term " unit dosage forms ", which refers to, to be suitable for as people
The physical discrete unit of the dosage unit of class patient and other mammals, each unit include predetermined quantity, be suitable for generate
The active material of required therapeutic effect and suitable pharmaceutical excipient.Typical unit dosage form includes liquid composition
Ampoule or syringe, or pill, tablet, capsule in solid composite prefilled, measure in advance etc..?
In this composition, the compound is usually less component (about 0.1 to about 50 weight %, or preferably from about 1 to about 40 weight
Measure %), remainder is the various carriers or excipient and processing aid useful for form of medication needed for being formed.
For oral dose, representative scheme is a daily oral dose.Using these dosage mode of administration, often
A dosage provides about 0.01 to about 50mg/kg the compounds of this invention, and preferred dosage respectively provides about 10 to about
40mg/kg, especially about 10 are to about 30mg/kg.
In order to provide with using the similar blood level of injection dosage, or than using the lower blood level of injection dosage,
Generally select transdermal dosage compositions, quantity is about 0.01 to about 20% weight, preferably approximately 0.1 to about 20% weight, preferably
About 0.1 to about 10% weight, and more preferably from about 0.5 to about 15% weight.
Liquid form suitable for oral administration may include suitable aqueous or nonaqueous carrier and buffer, suspending agent and divide
Powder, colorant, flavoring agent, etc..Solid form may include, for example, any following component, or the chemical combination with similarity
Object: adhesive, for example, microcrystalline cellulose, bassora gum or gelatin;Excipient, for example, starch or lactose, disintegrating agent, for example, brown
Alginic acid, Primogel or cornstarch;Lubricant, for example, magnesium stearate;Glidant, for example, colloidal silicon dioxide;Sweetener,
For example, sucrose or saccharin;Or flavoring agent, for example, peppermint, gaultherolin or orange flavoring.
The composition of injectable will be typically based in the Sterile Saline or phosphate buffered saline (PBS) or this field of injectable
The excipient of known other injectables.As previously mentioned, in such a composition, reactive compound is typically less group
Point, often about 0.05 to 10% weight, remainder is the excipient etc. of injectable.
Transdermal composition is typically formulated as to topical ointments or cream containing active component.When being formulated as ointment
When agent, active component is typically combined with paraffin or ointment bases miscible with water.Alternatively, active component can be with such as water packet
Oil type emulsifiable paste matrix is formulated as cream together.This preparation capable of permeating skin is it is well known in the art that and generally including for being promoted
Other components of the stable Cutaneous permeation of active component or preparation.All this known preparation capable of permeating skin and component are included in this
In the range of invention provides.
The compounds of this invention can also be given by transcutaneous device.Therefore, reservoir (reservoir) can be used in percutaneous dosing
Or porous film type or the patch of many kinds of solids matrix are realized.
Above-mentioned component for the oral composition given, inject or administered locally to is only representative.Other materials
And processing technology etc. is set forth in Remington's Pharmaceutical Sciences, 17th edition, 1985,
In the 8th part of Mack Publishing Company, Easton, Pennsylvania, it is incorporated by reference herein
The document.
The compounds of this invention can also be given with sustained release form, or give from sustained release administration system.It represents
The description of the sustained release materials of property can be found in Remington's Pharmaceutical Sciences.
The invention further relates to the pharmaceutically acceptable preparations of the compounds of this invention.In one embodiment, the system
Agent includes water.In another embodiment, the preparation includes cyclodextrine derivatives.The most common cyclodextrin be respectively by 6,
7 and 8 α-Isosorbide-5-Nitrae-connection glucose unit composition α-, β-and gamma-cyclodextrin optionally include in the saccharide part of connection
One or more substituent groups comprising but be not limited to: methylation, hydroxy alkylated, acylation and sulfoalkyl ether replaces.?
In some embodiments, the cyclodextrin is sulfoalkyl ether beta-cyclodextrin, for example, sulfobutyl ether beta-cyclodextrin, also referred to as
Captisol.See, e.g., U.S.5,376,645.In some embodiments, the preparation includes six propyl-beta-cyclodextrins
(for example, in water, 10-50%).
Indication
As used herein, term " the compounds of this invention " refers to formula (I) compound represented.The term further includes and formula (I)
Tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or the solvated compounds of compound.
The compounds of this invention is anti-influenza virus medicament, has the inhibitory activity to dependence endonuclease, so can
For treating and/or preventing epidemic infectious diseases.
Influenza virus is negative adopted single strand RNA virus, and is a member of family, orthomyxoviridae family.There is influenza disease in 3 at present
Poison: influenza virus A, influenza virus B and influenzavirus C.Influenza virus A have from host cell lipid film, it includes from
Virus surface hemagglutinin outstanding, neuraminidase and M2 protein.According to hemagglutinin (H or HA) and neuraminidase (N)
Influenza virus A is further classified.About 16 kinds of H antigens (H1 to H16) and 9 kinds of N antigen (N1 to N9).Influenza virus A packet
Include several hypotypes, including H1N1, H1N2, H2N2, H3N1, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1,
H7N2, H7N3, H7N7, H7N9, H9N2 and H10N7.The heterotrimer that influenza virus polymerase is made of following 3 kinds of subunits:
Polymerase acid (PA), polymerase alkali 1 (PB1) and polymerase alkali 2 (PB2).In the nucleus of infected cell, this polymerase
It is responsible for the duplication and transcription of viral RNA.PA subunit includes endonuclease activity position.The endonuclease activity cutting of PA is thin
Born of the same parents mRNA, subsequent cell mRNA are used as primer by PB1 subunit and synthesize for virus mRNA.
In some embodiments, a effective amount of the compounds of this invention or pharmaceutical composition as described herein can be used for treating
With/improve influenza infection.In other embodiments, a effective amount of the compounds of this invention or medicine group as described herein
Closing object can be used for flu-prevention virus infection.
In some embodiments, a effective amount of the compounds of this invention or pharmaceutical composition as described herein can be used for inhibiting
The duplication of influenza virus.In other embodiments, a effective amount of the compounds of this invention or pharmaceutical composition as described herein
It can be used for inhibiting influenza polymerase complex.In other embodiments, a effective amount of the compounds of this invention or described herein
Pharmaceutical composition can be used for inhibiting and/or reducing the activity of cap dependence endonuclease.In other embodiments, have
The compounds of this invention of effect amount or pharmaceutical composition as described herein can be used for inhibiting and/or reducing endonuclease cutting mRNA
Ability.
In some embodiments, the influenza infection can be influenza A virus infection.In other embodiments
In, the influenza infection can be influenza B virus infection.In other embodiments, the influenza infection can
To be influenza C virus infection.In some embodiments, the compounds of this invention can be used for treating and/or alleviating one kind of influenza
Or a variety of hypotypes.For example, the compounds of this invention can be used for treating H1N1 and/or H3N2.Additionally or alternatively, the compounds of this invention
It can be used for treating H2N2, H5N1 and/or H7N9.In some embodiments, the compounds of this invention is effective against more than a kind
The influenza of hypotype.For example, the compounds of this invention is effective against the influenza of 2,3,4 and/or 5 kind or more.
In some embodiments, a effective amount of the compounds of this invention or pharmaceutical composition comprising the compounds of this invention can
For treating and/or alleviating the infection of the upper respiratory tract as caused by (directly and/or indirectly) influenza infection.In some implementations
In scheme, a effective amount of the compounds of this invention or the pharmaceutical composition comprising the compounds of this invention can be used for treating and/or alleviating
The lower respiratory channel virus infection as caused by (directly and/or indirectly) influenza infection.In some embodiments, effective quantity
The compounds of this invention or pharmaceutical composition comprising the compounds of this invention can be used for treating and/or alleviating influenza infection
One or more symptoms are (for example, cough, throat pain, headache, nasal obstruction, fever or aversion to cold, muscle or joint are to pain, fatigue
Deng).In some embodiments, a effective amount of the compounds of this invention or the pharmaceutical composition comprising the compounds of this invention can be used for
Treatment and/or alleviation capillary bronchitis as caused by influenza infection and/or tracheobronchitis.In some embodiments
In, a effective amount of the compounds of this invention or the pharmaceutical composition comprising the compounds of this invention can be used for treating and/or alleviating due to
Pneumonia caused by influenza infection.
In some embodiments, a effective amount of the compounds of this invention or pharmaceutical composition comprising the compounds of this invention can
For mitigating the severity of one or more symptoms of influenza infection.The example of symptom include, but are not limited to it is following, fever,
Shiver with cold, cough, sore-throat, rhinorrhea, nasal obstruction, DOMS, physical distress, headache, fatigue, vomiting and/or diarrhea.
In some embodiments, the effective quantity of the compounds of this invention effectively can make virus titer be reduced to reduced levels
Amount, for example, about 10E4TCID50/mL (TCID=tissue culture infection dose) is to about 10E3TCID50/mL or to about
100TCID50/mL or to about 10TCID50/mL.In some embodiments, the effective quantity of the compounds of this invention are as follows: with give
Virus load before formula (I) compound is compared, and the amount of virus load is effectively reduced.For example, wherein in the change for giving formula (I)
Virus load is detected before closing object, and is detected again after being started using the therapeutic scheme of the compound of formula (I) (for example, treatment
1-2 days after beginning).In some embodiments, the effective quantity of the compounds of this invention, which can be, effectively reduces virus load
To the amount for being below about 10E4TCID50/mL.In some embodiments, the effective quantity of the compounds of this invention are as follows: in giving construction
(I) the virus load before compound is compared, and the virus titer in effective nose/pharynx for realizing individual or nasal douche sample is such as
The reduced amount of lower range: reducing about 1.5-log to about 2.5-log or reduces about 3-log to about 4-log.For example, wherein existing
Virus load is detected before giving the compound of formula (I), and virus load is detected before the compound using formula (I), and
(for example, treatment starts latter 1-2 days) is detected after starting using the therapeutic scheme of the compound of formula (I) again.
In some embodiments, compared with the individual of untreated, the compounds of this invention can produce one or more lifes
Total quality health living, such as compared with the individual of untreated, disease duration greatly reduces, disease severity reduces,
The time for being restored to the time reduction of normal health and normal activity and mitigating one or more symptoms of virus infection subtracts
It is few.In some embodiments, compared with the individual of untreated, the compounds of this invention can cause related with virus infection one
The reduction of the length and/or severity of kind or a variety of symptoms.In some embodiments, compared with the individual of untreated,
The compounds of this invention can cause it is related with virus infection, include but is not limited to tympanitis (ear inflammation) sinusitis, bronchitis
With the reduction of one or more complications of pneumonia.
In some embodiments, relative to level before the treatment of individual, the compounds of this invention can cause virus replication to subtract
It is at least 1,2,3,4,5,10,15,20,25,75,100 times or more few, as being measured after therapeutic scheme starts.
After a period of time, infectious agent can develop to it is one or more treatment and drug resistance.Term as used herein is " anti-
Pharmacological property " refers to the virus strains to one or more therapeutic agent display delays, reduction and/or zero reaction.For example, using disease-resistant
After toxic agent treatment, compared with the amount of the virus load reduction shown by the individual for infecting non-drug-fast strain, drug-resistant pathogen is infected
The virus load of the individual of poison can be reduced to smaller extent.In some embodiments, can to infected resist it is one or more not
Individual with the influenza virus of anti influenza medicament (for example, amantadine and/or Oseltamivir) gives the compounds of this invention.One
In a little embodiments, the compounds of this invention can be given to the individual for the influenza virus for having infected anti-M2 protein inhibitor.Some
In embodiment, compared with influenza strain resists the development of other flu pharmaceuticals, but when use the compounds of this invention treatment individual, resist
The development of pharmacological property influenza strain postpones.
In some embodiments, compared with the individual percentage for undergoing the complication treated using Oseltamivir, this hair
Bright compound can reduce the individual percentage of complication of the experience from influenza infection.For example, using the compound of formula (I)
The percentage of the Individual Experience complication for the treatment of is few 10% using individual that Oseltamivir is treated, 20%, 30%, 40%, 60%,
70%, 80% and 90%.
In some embodiments, the individual percentage of the Baloxavir marboxil complication treated is used with experience
It compares, the compounds of this invention can reduce the individual percentage of complication of the experience from influenza infection.For example, using formula
(I) individual that the percentage of the Individual Experience complication of compound treatment is treated using Baloxavir marboxil is few
10%, 20%, 30%, 40%, 60%, 70%, 80% and 90%.
Conjoint therapy
In some embodiments, the compounds of this invention, or the pharmaceutical composition including compound described herein can be with one
Kind or a variety of additional pharmaceutical agent combinations use.In some embodiments, the compounds of this invention can exist at present with one or more
Treat the use of pharmaceutical agent combinations used in the routine care standard of influenza.For example, the additional medicament can be amantadine (gold
Rigid alkane -1- amine, Symmetrel), rimantadine (Flumadine), zanamivir (Relenza) and Oseltamivir
(Tamiflu).Treatment for influenza, additional medicament includes but is not limited to: neuraminidase inhibitor, M2 albumen inhibit
Agent, polymerase inhibitors, PB2 inhibitor, Peramivir, La Nina's rice Wei, Favipiravir, La Nina's rice Wei caprylate, influenza
Enzyme (DAS181, NexBio), ADS-8902 (amantadine HCl/ Oseltamivir/Ribavirin, Adamas
Pharmaceuticals), immunomodulator (for example, I type interferon), beraprost, Ribavirin etc..
In some embodiments, the compounds of this invention can be combined with one or more additional medicaments with single medicine
Object is administered together.In some embodiments, the compounds of this invention can with one or more additional medicaments as two kinds or
More kinds of individual pharmaceutical composition administrations.For example, the compounds of this invention can be administered with a kind of pharmaceutical composition, and at least
A kind of additional medicament can be administered with second of pharmaceutical composition.It is if there is at least two additional medicaments, then described additional
The one or more of medicament may be present in the first pharmaceutical composition comprising the compounds of this invention and other are additional
At least one of medicament may be present in second of pharmaceutical composition.The compounds of this invention and one or more additional medicaments
Order of administration is alterable.In some embodiments, the compounds of this invention can be given before all additional medicaments.At other
In embodiment, the compounds of this invention can be given before at least one additional medicament.It is still in other embodiments, originally
Invention compound can be administered simultaneously with one or more additional medicaments.Still still in other embodiments, it can give
The compounds of this invention is given after at least one additional medicament.In some embodiments, all additional medicines can given
The compounds of this invention is given after agent.
In some embodiments, the combination that the compounds of this invention combines one or more additional medicaments can lead to cumulative
Effect.In some embodiments, the combination that the compounds of this invention combines one or more additional medicaments can lead to collaboration effect
It answers.In some embodiments, the combination that the compounds of this invention combines one or more additional medicaments can lead to strong association
Same effect.In some embodiments, the combination that the compounds of this invention combines one or more additional medicaments is not antagonism.
As used herein, term " antagonism " is meant: compared with the summation of compound activity in combination, when individually surveying
(single compound is used as) when the activity of fixed each compound, and the activity of compound combination is lower.As used herein, term
" synergistic effect " is meant: when individually measuring the activity of each compound, the activity of compound combination is greater than compound in combination
Independent active summation.As used herein, term " additive effect " is meant: when individually measuring the activity of each compound,
The activity of compound combination is approximately equal to the independent active summation of compound in combination.
Using with one or more additional medicament (including its pharmaceutically acceptable salt and prodrug) groups as described above
The potential advantage of the compounds of this invention of conjunction may is that and work as in the compound or its pharmaceutically acceptable salt for being free of formula (I)
In the case where give one or more additional medicaments (including its pharmaceutically acceptable salt and prodrug) Shi Shixian identical treatment
As a result amount required for is compared, and the one or more additional of morbid state disclosed herein (for example, influenza) is effectively treated
Amount required for medicament (including its pharmaceutically acceptable salt and prodrug) decreases.For example, when with administered as monotherapy
Realize the amount phase of medicament (including its pharmaceutically acceptable salt and prodrug) additional required for identical virus load is reduced
Than, additional medicament (including its pharmaceutically acceptable salt and prodrug) as described above when with the compounds of this invention combination medicine-feeding
When amount can be less.Using with one or more as described above additional medicaments (including its pharmaceutically acceptable salt and
Prodrug) combination the compounds of this invention another potential advantage is that: with barrier phase when giving compound with monotherapy
Than the more Gao Ping to form drug-resistant pathogen toxic bacterial strain can be established using two or more compounds with different role mechanism
Barrier.
The method for preparing the compounds of this invention
Known organic synthesis technology can be used to prepare for the compounds of this invention (including its salt), and can be according to a variety of possible conjunctions
At any one of approach (those of in all schemes as follows) Lai Hecheng.The reaction for being used to prepare the compounds of this invention can close
It is carried out in suitable solvent, the technical staff of organic synthesis field is readily able to select solvent.Suitable solvent can reacted
Temperature (for example, in temperature that solvent freezes in temperature to solvent boiling point temperature range) under with initial substance (reactant), in
Mesosome or product do not react substantially.Set reaction can carry out in the mixture of a kind of solvent or more than one solvents.Technology
Personnel can select the solvent for specific reaction step according to specific reaction step.
The preparation of the compounds of this invention can be related to the protection and removal protection of different chemical groups.Those skilled in the art can
It easily determines whether to need to protect and remove protection and the selection of suitable protecting base.The chemical property of protecting group can be found in example
Such as Wuts and Greene, Protective Groups in Organic Synthesis, the 4th edition, John Wiley&Sons:
New Jersey, (2006) are incorporated herein by reference in their entirety.
The compounds of this invention can be reacted by the racemic mixture of compound with optically active resolving agent to be formed it is a pair of non-
Enantiomter compound separates diastereoisomer and recycles the enantiomer of optical purity, is prepared into its single alloisomerism
Body.The non-enantiomer derivative of the compounds of this invention can be used to carry out when Chiral Separation, the compound (example that can preferentially dissociate
Such as, crystallization of diastereomeric salt).Diastereomer has dramatically different physical property (for example, fusing point, boiling point, solubility, reaction
Property etc.), and separation can be readily derived by the advantage of these dissimilarities.Diastereomer can preferably pass through base by chromatography
It is separated in separation/fractionation technology of the difference of solubility.Then by will not racemization any practical means, recycling light
Pure enantiomer is learned, together with resolution reagent.The technology of compound stereoisomer is obtained suitable for splitting since racemic mixture
More detailed description be found in Jean Jacques, Andre Collet, Samue1H.Wilen, " enantiomer, raceme and
Split " (" Enantiomers, Racemates and Resolutions "), John Wiley And Sons, Inc., 1981.
Reaction can be monitored according to any suitable method known in the art.For example, spectrum means (such as nuclear-magnetism can be passed through
Resonance (NMR) spectroscopic methodology (such as1H or13C), infrared (IR) spectroscopic methodology, spectrophotometry (for example, UV- visible light), mass spectrum
(MS)) it or by chromatographic process (such as high performance liquid chromatography (HPLC) or thin-layered chromatography (TLC)) to monitor product is formed.
In common synthetic method and embodiment, the meaning respectively abridged is as described below.
Boc: tert-butoxycarbonyl
DBU: diazabicycloundecene
DMA:N, N- dimethyl acetamide
DMF:N, dinethylformamide
NMP:N- methyl pyrrolidone
THF: tetrahydrofuran
OBn: benzyloxy
T3P: propyl phosphonous acid acid anhydride
PPT: para-methylbenzenepyridinsulfonate sulfonate
MSA: methanesulfonic acid
ACN: acetonitrile
MTBE: methyl tertiary butyl ether(MTBE)
Formula (I) compound of the present invention can be by being prepared as following reaction route 1:
Reaction route 1
Wherein R3、R7-R15It is each independently selected from hydrogen or deuterium, and R3、R7-R15It is not all hydrogen.
Formula (C) compound can by formula (A) compound and formula (B) compound in suitable condensing agent (for example, propyl phosphoric acid
Acid anhydride (T3P), methanesulfonic acid or p-methyl benzenesulfonic acid), suitable solvent is (for example, DMF, DMA, NMP, THF, ethyl acetate, acetic acid fourth
Ester, dioxane equal solvent or these mixed solvent) and suitable alkali (such as sodium carbonate, potassium carbonate, cesium carbonate etc.) exist
Lower reaction.The temperature range reacted at about 10 DEG C to 80 DEG C carries out, and can need to complete in about 1-24 hours.Formula (I-1) compound can
It is left away and is synthesized (for example, using protective Groups in from formula (C) compound by blocking group Bn
Organic Synthesis, Theodora W Green (progress of usual method documented by John Wiley&Sons etc.).Formula
(I-2) compound can be by formula (I-1) compound and formula (D) compound in suitable alkali (such as sodium carbonate, potassium carbonate, carbonic acid
Caesium etc.) in the presence of using hydroxyl be converted into the usual method of ether (for example, Protective Groups in can be applied
Organic Synthesis,Theodora W Green(John Wiley&Sons)、Prog.Med,5:2157-2161
(1985) and side documented by Supplied by The British Library-" The word ' s Knowledge " etc.
Method) and obtain formula (I-2) compound.
Formula (A-1) compound can be prepared by following reaction route 2:
Reaction route 2
The preparation route and synthetic method of formula (A-1) compound and formula (E-1) disclose in WO2017/221869A1.
Formula (A-2) compound can be prepared by following reaction route 3:
Reaction route 3
The preparation route and the same formula of synthetic method (A-1) compound of formula (A-2) compound, difference deuterated compound
F-2 replaces compound F-1.
Formula (B-1) compound and formula (B-2) compound can be prepared by following reaction route 4:
Reaction route 4
The preparation route and synthetic method of formula (B-1) compound disclose in WO2017/221869A1.Formula (B-2) is changed
The contract method and formula (B-1) compound for closing object are the difference is that final step is substituted with deuterated metallic reducing agent
NaBH4。
The preparation of midbody compound 9
Synthetic route is as follows:
The synthesis of step 1 compound 3
Compound 1 (2.0g, 1.05mmol) and compound 2 (2.3g, 1.7mmol) are added in DMA (20ml) solution,
Solution is heated to 40 DEG C, is then slowly added into sodium tert-butoxide (1.6g, 1.6mmol), is stirred to react at 40 DEG C 3 hours, is reacted
It is cooled to room temperature after completely, it is about 7 that acetic acid tune pH value, which is then slowly added dropwise, and 10ml water is added, and is extracted with methylene chloride (50ml × 3)
It taking, merges organic phase, anhydrous sodium sulfate is dry, concentrate progress post separation (eluant, eluent: petrol ether/ethyl acetate (v/v)=
10:1), white solid 2.1g, yield 72% are obtained.
The synthesis of step 2 compound 4
Compound 3 (2.0g, 7.2mmol) is added in ethyl alcohol (10ml) and water (10ml), solution is heated to 60 DEG C,
Then hydrazine hydrate (0.7g, 14.3mmol) is added, is stirred to react 4 hours at 60 DEG C, slowly add 20% hydrogen-oxygen after fully reacting again
Changing sodium water solution tune pH is about 13, is extracted with methylene chloride (100ml × 3), and organic phase is merged, and anhydrous sodium sulfate is dry, concentration,
Concentrate is directly thrown in next step.
The synthesis of step 3 compound 6
Successively by compound 5 (5.0g, 20.5mmol), iodomethane (3.5g, 24.4mmol), DBU (6.3g, 40.7mmol)
It is added into DMF (20ml) liquid, which reacts 20h at room temperature, 80ml water is then added, then with ethyl acetate (60ml
× 3) it extracts, merges organic phase, anhydrous sodium sulfate is dry, and concentrate carries out post separation (eluant, eluent: petrol ether/ethyl acetate
(v/v)=5:1), obtain yellow solid 3.6g, yield 69%.
The synthesis of step 4 compound 7
Successively by compound 6 (0.5g, 1.8mmol), para-methylbenzenepyridinsulfonate sulfonate (1.38g, 5.5mmol), NH2NHBoc
(0.36 g, 2.7mmol) is added into DMA (10ml) liquid, and 15h is reacted at 60 DEG C, 20ml water is then added, then with acetic acid second
Ester (30ml × 3) extraction merges organic phase, and anhydrous sodium sulfate is dry, and concentrate carries out post separation (eluant, eluent: petroleum ether/acetic acid
Ethyl ester (v/v)=4:1), obtain yellow solid 0.6g, yield 80%.
The synthesis of step 5 compound 8
Successively by compound 7 (1.0g, 2.7mmol), compound 4 (0.8g, 5.3mmol), it is added to THF (20ml) liquid
In, 2 drop DBU are then added dropwise, which reacts 20h at 60 DEG C, is then spin-dried for reaction solution, is added 20ml water, then with acetic acid second
Ester (30ml × 3) extraction merges organic phase, and anhydrous sodium sulfate is dry, and concentrate carries out post separation (eluant, eluent: petroleum ether/acetic acid
Ethyl ester (v/v)=4:1), obtain solid 0.7g, yield 54%.
The synthesis of step 6 compound 9
Successively compound 8 (1.5g, 3.1mmol), methanesulfonic acid (0.43g, 4.5mmol) are added to acetonitrile (20ml) liquid
In, which reacts 5h at 60 DEG C, is then spin-dried for reaction solution, 20ml water is added, then extracted with ethyl acetate (30ml × 3),
Merging organic phase, anhydrous sodium sulfate is dry, and concentrate carries out post separation (eluant, eluent: petrol ether/ethyl acetate (v/v)=1:2),
Obtain solid 0.5g, yield 51%.
The preparation of midbody compound 17
Synthetic route is as follows:
The synthesis of step 1 compound 11
Under the conditions of 0 DEG C, by LiAlD4(7.2g, 170.9mmol) be slowly added into compound 10 (10.0g,
In tetrahydrofuran (150ml) solution 85.6mmol), reaction solution is warming up to back flow reaction 10h again after adding.After fully reacting
It is cooled to 0 DEG C, then plus water quenching reaction, diatomite filtering are directly spin-dried for filtrate, obtain liquid 4.4g, directly throw next step.
The synthesis of step 2 compound 13
Successively by compound 12 (5.0g, 34.0mmol), compound 11 (4.4g, 68.0mmol), nine water ferric nitrates
(1.3g, 3.4mmol) is added into toluene (40ml) liquid, which reacts 15h at 115 DEG C, and 20ml water is then added,
It being extracted again with ethyl acetate (50ml × 3), merges organic phase, anhydrous sodium sulfate is dry, concentrate progress post separation (eluant, eluent:
Petrol ether/ethyl acetate (v/v)=5:1), obtain white solid 3.9g, yield 59%.
The synthesis of step 3 compound 14
Compound 13 (4.0g, 21.0mmol) and compound 2 (4.6g, 34mmol) are added in DMA (20ml) solution,
Solution is heated to 40 DEG C, is then slowly added into sodium tert-butoxide (3.2g, 3.2mmol), is stirred to react at 40 DEG C 3 hours, is reacted
It is about 7 that acetic acid tune pH value is slowly added dropwise after completely again, and 10ml water is added, is extracted with methylene chloride (50ml × 3), merges organic
Phase, anhydrous sodium sulfate is dry, and concentrate carries out post separation (eluant, eluent: petrol ether/ethyl acetate (v/v)=10:1), obtains white
Color solid 3.7g, yield 63%.
The synthesis of step 4 compound 15
Compound 14 (2.0g, 7.2mmol) is added in ethyl alcohol (10ml) and water (10ml), solution is heated to 60
DEG C, hydrazine hydrate (0.7g, 14.3mmol) then is added, is stirred to react 4 hours at 60 DEG C, slowly adds 20% hydrogen after fully reacting again
Aqueous solution of sodium oxide tune pH value is about 13, is extracted with methylene chloride (100ml × 3), and organic phase is merged, and anhydrous sodium sulfate is dry,
Concentration, concentrate are directly thrown in next step.
The synthesis of step 5 compound 16
Successively compound 7 (1.0g, 2.7mmol) and compound 15 (0.8g, 5.3mmol) are added to THF (20ml) liquid
In, 2 drop DBU are then added dropwise, which reacts 20h at 60 DEG C, is then spin-dried for reaction solution, is added 20ml water, then with acetic acid second
Ester (30ml × 3) extraction merges organic phase, and anhydrous sodium sulfate is dry, and concentrate carries out post separation (eluant, eluent: petroleum ether/second
Acetoacetic ester (v/v)=4:1), obtain solid 0.8g, yield 60%.
The synthesis of step 6 compound 17
Successively compound 16 (1.0g, 2.1mmol) and methanesulfonic acid (0.3g, 3.0mmol) are added to acetonitrile (20ml) liquid
In, which reacts 5h at 60 DEG C, is then spin-dried for reaction solution, 20ml water is added, then extracted with ethyl acetate (30ml × 3),
Merging organic phase, anhydrous sodium sulfate is dry, and concentrate carries out post separation (eluant, eluent: petrol ether/ethyl acetate (v/v)=1:2),
Obtain solid 0.45g, yield 68%.
The preparation of midbody compound 23
Synthetic route is as follows:
The synthesis of step 1 compound 19
Under nitrogen protection, compound L DA (35ml, 70mmol) is added into anhydrous THF (50ml) liquid, solution drop
To after -40 DEG C, be then added dropwise again in the tetrahydrofuran solution of compound 18 (5g, 31.6mmol), after adding at such a temperature after
Continuous reaction 1.5h, is then slowly added into DMF (5.74g, 78.5mmol) into above-mentioned reaction solution again, adds hydrochloric acid after adding
(34ml, 6 mol/L), are stirred for ten minutes, then are extracted with ethyl acetate (50ml × 3), merge organic phase, and anhydrous sodium sulfate is dry
It is dry, it is concentrated to get yellow liquid 6g.
The synthesis of step 2 compound 20
Benzenethiol (3.9g, 35.4mmol) and d-camphorsulfonic acid (1.6g, 5.0mmol) are added to above compound 6
Toluene solution in, 4h is then stirred to react at 60 DEG C, after fully reacting, 0 DEG C when cooling, sodium hydroxide is then added
(10ml, 2mol/L) is being washed with water then with toluene extraction (20ml × 3) extraction, merges organic phase, and anhydrous sodium sulfate is dry
Dry, concentration, concentrate is directly thrown in next step.
The synthesis of step 3 compound 21
Alchlor (5.52g, 41.4mmol) is added in toluene (30ml), solution is cooled to 0 DEG C, then by four
Tetramethyldisiloxane (5.56g, 41.4mmol) is slowly added dropwise in above-mentioned solution, then at room temperature by compound 20 again slowly
It is added in above-mentioned solution, reacts 3h after adding at room temperature, slowly add 15% sulfuric acid (35ml) again after fully reacting, then use second
Acetoacetic ester (50ml × 3) extraction merges organic phase, and anhydrous sodium sulfate is dry, and concentration is dry, then is beaten with petroleum ether, obtains white
Solid 7g, 79%.
The synthesis of step 4 compound 22
Compound 21 (7.0g, 25.0mmol) is added in polyphosphoric acids (30ml), solution is warming up to 120 DEG C, it should
At a temperature of react 3h, slowly reaction solution is poured into ice water again after fully reacting, then with ethyl acetate (60ml × 3) extract,
Merging organic phase, anhydrous sodium sulfate is dry, and concentration is dry, then is beaten with petroleum ether, obtain white solid 5g, 77%.
The synthesis of step 5 compound 23
Under the conditions of 40 DEG C, by NaBH4(0.4g, 11.5mmol) is added to the isopropyl of compound 22 (2.0g, 7.6mmol)
In alcohol alcohol (20ml) solution, reaction 1h is then proceeded to.Then it is reacted with the hydrochloric acid of 1M, methylene chloride (30ml × 2) extraction,
Merge organic phase, anhydrous sodium sulfate, which dries, filters, to be spin-dried for, and gray solid product 1.8g is obtained.
The synthesis of midbody compound 24
Using following synthetic route:
Under the conditions of 40 DEG C, by NaBD4(0.5g, 11.5mmol) is added to the isopropyl of compound 22 (2.0g, 7.6mmol)
In alcohol alcohol (20ml) solution, reaction 1h is then proceeded to.Then it is reacted with the hydrochloric acid of 1M, methylene chloride (30ml × 2) extraction,
Merge organic phase, anhydrous sodium sulfate, which dries, filters, to be spin-dried for, and gray solid product 1.8g is obtained.
(((12aR) -12- (fluoro- 6,11- dihydro-dibenzo (B, the E) thiepin -11- base-of (11S) -7,8- two of embodiment 1
11-d) -6,8- dioxo -3,4,6,8,12,12a- hexahydro -1H- (1,4) oxazines (3,4-C) pyrido (2,1-F) (1,2,4)
Triazine -7- base) oxygroup) methyl carbonic acid methyl esters (compound T-1) preparation
Synthetic route is as follows
The synthesis of step 1 compound 25
Successively by compound 9 (0.5g, 1.5mmol), compound 24 (0.45g, 1.5mmol) and T3P (0.73g,
It 2.3mmol) is added into ethyl acetate (6ml) liquid, then adds methanesulfonic acid (0.29g, 3.0mmol), which exists,
6 h are reacted at 70 DEG C, 10ml water are then added, then extracted with ethyl acetate (20ml × 3), are merged organic phase, anhydrous sodium sulfate
Dry, concentrate carries out post separation (eluant, eluent: petrol ether/ethyl acetate (v/v)=1:2), obtains white solid 0.6g, yield
69%.
The synthesis of step 2 compound 26
Compound 25 (0.6g, 1.0mmol) and lithium chloride (0.23g, 5.0mmol) are added in DMA (10ml), it will be molten
Liquid is warming up to 80 DEG C, reacts 3h at this temperature, again slowly pours into reaction solution in ice water after fully reacting, then uses ethyl acetate
(20 ml × 3) extraction merges organic phase, and anhydrous sodium sulfate is dry, and concentration is dry, then is beaten with MTBE, obtains white solid
0.4g, yield 81%.
The synthesis of step 3 compound 27
Successively by compound 26 (0.3g, 0.61mmol), methyl chloromethyl ester (0.15g, 1.3mmol), potassium carbonate
(0.2g, 1.22mmol), potassium iodide (0.1g, 0.61mmol) are added into DMA (6ml) liquid, which exists, anti-at 50 DEG C
6h is answered, 10ml water is then added, then extracted with ethyl acetate (20ml × 3), merges organic phase, anhydrous sodium sulfate is dry, concentration
Liquid carries out post separation (eluant, eluent: DCM/MeOH (v/v)=20:1), obtains white solid 0.21g.
The synthesis of step 4 compound T-1
The compound 27 of 0.21g is dissolved in 20mL methanol, (instrument: SFC-80 is prepared using following condition
(Thar,Waters);Chiral column: OJ-H 20*250mm, 10um (Daicel);Column temperature: 35 DEG C;Mobility: CO2/ methanol (contains
0.2% ammonia methanol)=87/13;Flow velocity: 80g/min;Column pressure: 100bar;Detection wavelength: 214nm;Circulation time: 6.0min;
Each sampling volume: 1.0mL), four isomers are obtained, chiral analysis (instrument: Agilent is carried out using following condition
1200;Chiral column: IG 4.6 × 250mm, 5um (Decial);Column temperature: 25 DEG C;Mobile phase: n-hexane (contains 0.1 diethylamine):
Ethyl alcohol (containing 0.1% diethylamine)=60:40;Flow velocity: 1.0mL/min;Detection wavelength: 214nm;Sample volume: 15uL), wherein protecting
Staying time=35.65min is compound T-1, white compound 45mg.LC-MS:m/z=573.2 (M+1)+,UV 214;1H
NMR(500MHz,CDCl3)δ/ppm:7.14-7.08(m,4H), 7.03-7.00(m,1H),6.89-6.87(m,1H),6.83-
6.81 (m, 1H), 5.99 (s, 2H), 5.87 (d, J=7.5Hz, 1H), 5.27 (dd, J=14.0 Hz, J=2.5Hz, 1H),
4.63 (dd, J=14.0Hz, J=2.5Hz, 1H), 4.51 (dd, J=10.0Hz, J=2.5Hz, 1H), 4.06 (d, J=14.0
Hz, 1H), 3.93 (dd, J=11.0Hz, J=3.0Hz, 1H), 3.86 (s, 3H), 3.76 (dd, J=11.0Hz, J=3.0Hz,
1H), 3.55 (t, J=10. 5Hz, 1H), 3.46-3.41 (m, 1H), 2.96-2.91 (m, 1H)
(((12aR) -12- (fluoro- 6,11- dihydro-dibenzo (B, the E) thiepin -11- base-of (11S) -7,8- two of embodiment 2
11-d) -6,8- dioxo -3,4,6,8,12,12a- hexahydro -1H- (1,4) oxazines (3,4-C) pyrido (2,1-F) (1,2,4)
Triazine -7- base -3,3,4,4-d4) oxygroup) and methyl carbonic acid methyl esters (compound T-2) preparation
Synthetic route is as follows
The synthesis of step 1 compound 28
Successively by compound 17 (0.5g, 1.5mmol), compound 24 (0.45g, 1.5mmol) and T3P (0.73g,
It 2.3mmol) is added into ethyl acetate (6ml) solution, then adds methanesulfonic acid (0.29g, 3.0mmol), the reaction solution
6h is being reacted at 70 DEG C, 10ml water is then added, then extracted with ethyl acetate (20ml × 3), is merged organic phase, anhydrous slufuric acid
Sodium is dry, and concentrate carries out post separation (eluant, eluent: petrol ether/ethyl acetate (v/v)=1:2), obtains white solid 0.55g,
Yield 60%.
The synthesis of step 2 compound 29
Compound 28 (0.5g, 0.86mmol) and lithium chloride (0.2g, 4.3mmol) are added in DMA (10ml), it will be molten
Liquid is warming up to 80 DEG C, reacts 3h at this temperature, again slowly pours into reaction solution in ice water after fully reacting, then uses ethyl acetate
(20 ml × 3) extraction merges organic phase, and anhydrous sodium sulfate is dry, and concentration is dry, then is beaten with MTBE, obtains white solid
0.33g, 78%.
The synthesis of step 3 compound 30
Successively by compound 29 (0.33g, 0.67mmol), methyl chloromethyl ester (0.20g, 1.4mmol), potassium carbonate
(0.25g, 1.4mmol) and potassium iodide (0.1g, 0.67mmol) are added into DMA (6ml) solution, which exists, at 50 DEG C
6h is reacted, 10ml water is then added, then extracted with ethyl acetate (20ml × 3), merges organic phase, anhydrous sodium sulfate is dry, dense
Contracting liquid carries out post separation (eluant, eluent: DCM/MeOH (v/v)=20:1), obtains white solid 0.25g.
The synthesis of step 4 compound T-2
The compound 30 of 0.25g is dissolved in 25mL methanol, (instrument: SFC-80 is prepared using following condition
(Thar,Waters);Chiral column: OJ-H 20*250mm, 10um (Daicel);Column temperature: 35 DEG C;Mobility: CO2/ methanol (contains
0.2% ammonia methanol)=87/13;Flow velocity: 80g/min;Column pressure: 100bar;Detection wavelength: 214nm;Circulation time: 6.0min;
Each sampling volume: 1.0mL), four isomers are obtained, chiral analysis (instrument: Agilent is carried out using following condition
1200;Chiral column: IG 4.6 × 250mm, 5um (Decial);Column temperature: 25 DEG C;Mobile phase: n-hexane (contains 0.1 diethylamine):
Ethyl alcohol (containing 0.1% diethylamine)=60:40;Flow velocity: 1.0mL/min;Detection wavelength: 214nm;Sample volume: 15uL), wherein protecting
Staying time=36.53min is compound T-2, white compound 50mg.LC-MS:m/z=577.3 (M+1)+,UV 214;1H
NMR(500MHz,CDCl3)δ/ppm:7.14-7.08(m,4H), 7.03-7.00(m,1H),6.89-6.87(m,1H),6.83-
6.81 (m, 1H), 5.99 (s, 2H), 5.87 (d, J=7.5Hz, 1H), 5.27 (dd, J=14.0 Hz, J=2.5Hz, 1H),
4.51 (dd, J=10.0Hz, J=2.5Hz, 1H), 4.06 (d, J=14.0Hz, 1H), 3.93 (dd, J=11.0Hz, J=3.0
Hz, 1H), 3.86 (s, 3H), 3.55 (t, J=10.5Hz, 1H), 3.12-3.08 (m, 1H)
(((the 12aR) -12- (fluoro- 6,11- dihydro-dibenzo (B, the E) thiepin -11- base of (11S) -7,8- two)-of embodiment 3
6,8- dioxo -3,4,6,8,12,12a- hexahydro -1H- (1,4) oxazines (3,4-C) pyrido (2,1-F) (1,2,4) triazine -7-
Base) oxygroup) methyl carbonic acid (methyl-d3) ester (compound T-3) preparation
Synthetic route is as follows
Step 1 compound carbonic acid (methyl-d3) chloromethyl ester synthesis
Deuterated methanol (1.0g, 28.7mmol) and triethylamine (3.4g, 34.2mmol) are added to methylene chloride (30ml)
In, solution is cooled to 0 DEG C, then chloro-methyl-chloroformate (3.7g, 28.7mmol) is slowly added drop-wise in above-mentioned solution, then
3h is reacted at room temperature, water (10ml) is quenched after fully reacting, DCM (20ml) extraction merges organic phase, and anhydrous sodium sulfate is dry
Dry, concentration is dry, obtains liquid 2.8g, yield 78%.
The synthesis of step 2 compound 31
Successively by compound 9 (0.8g, 2.45mmol), compound 23 (0.65g, 2.45mmol) and T3P (1.2g,
It 3.7mmol) is added into ethyl acetate (6ml) solution, then adds methanesulfonic acid (0.45g, 4.9mmol), which exists
6h is reacted at 70 DEG C, 10ml water is then added, then extracted with ethyl acetate (20ml × 3), is merged organic phase, anhydrous sodium sulfate is dry
Dry, concentrate carries out post separation (eluant, eluent: petrol ether/ethyl acetate (v/v)=1:2), obtains white solid 0.9g, yield
64%.
The synthesis of step 3 compound 32
Compound 31 (0.9g, 1.57mmol) and lithium chloride (0.33g, 7.85mmol) are added in DMA (10ml), it will
Solution is warming up to 80 DEG C, reacts 3h at this temperature, again slowly pours into reaction solution in ice water after fully reacting, then uses acetic acid second
Ester (20 ml × 3) extraction merges organic phase, and anhydrous sodium sulfate is dry, and concentration is dry, then is beaten with MTBE, obtains white solid
0.6g, 79%.
The synthesis of step 4 compound 33
Successively by compound 32 (0.6g, 1.2mmol), carbonic acid (methyl-d3) chloromethyl ester (0.3g, 2.4mmol), potassium carbonate
(0.4g, 2.4mmol) and potassium iodide (0.2g, 1.2mmol) are added into DMA (6ml) liquid, which reacts at 50 DEG C
Then 6h is added 10ml water, then is extracted with ethyl acetate (20ml × 3), merge organic phase, anhydrous sodium sulfate is dry, concentrate
It carries out post separation (eluant, eluent: DCM/MeOH (v/v)=20:1), obtains white solid 0.55g.
The synthesis of step 5 compound T-3
0.55g compound 33 is dissolved in 50mL methanol, prepared using following condition (instrument: SFC-80 (Thar,
Waters);Chiral column: OJ-H 20*250mm, 10um (Daicel);Column temperature: 35 DEG C;Mobility: CO2/ methanol (contains 0.2% ammonia
Methanol)=87/13;Flow velocity: 80g/min;Column pressure: 100bar;Detection wavelength: 214nm;Circulation time: 6.0min;Each sample introduction
Volume: 1.0mL), four isomers are obtained, chiral analysis (instrument: Agilent 1200 is carried out using following condition;Chiral column:
IG 4.6×250mm,5um (Decial);Column temperature: 25 DEG C;Mobile phase: n-hexane (contains 0.1 diethylamine): ethyl alcohol (contains 0.1%
Diethylamine)=60:40;Flow velocity: 1.0mL/min;Detection wavelength: 214nm;Sample volume: 15uL), wherein retention time=
37.24min is compound T-3, white solid 100mg.LC-MS:m/z=575.0 (M+1)+,UV 214;1H NMR
(500MHz,CDCl3)δ/ppm:7.14-7.08(m,4H), 7.03-7.00(m,1H),6.89-6.87(m,1H),6.83-
6.81 (m, 1H), 5.99 (s, 2H), 5.87 (d, J=7.5Hz, 1H), 5.33 (s, 1H), 5.27 (dd, J=14.0Hz, J=
2.5Hz, 1H), 4.63 (dd, J=14.0Hz, J=2.5Hz, 1H), 4.51 (dd, J=10.0Hz, J=2.5Hz, 1H), 4.06
(d, J=14.0Hz, 1H), 3.93 (dd, J=11.0Hz, J=3.0Hz, 1H), 3.76 (dd, J=11.0Hz, J=3.0Hz,
1H), 3.55 (t, J=10.5Hz, 1H), 3.46-3.41 (m, 1H), 2.96-2.91 (m, 1H)
(((12aR) -12- (fluoro- 6,11- dihydro-dibenzo (B, the E) thiepin -11- base-of (11S) -7,8- two of embodiment 4
11-d) -6,8- dioxo -3,4,6,8,12,12a- hexahydro -1H- (1,4) oxazines (3,4-C) pyrido (2,1-F) (1,2,4)
Triazine -7- base) oxygroup) methyl carbonic acid (methyl-d3) ester (compound T-4) preparation
Synthetic route is as follows
The synthesis of step 1 compound 34
Successively by compound 26 (0.5g, 1.01mmol), carbonic acid (methyl-d3) chloromethyl ester (0.26g, 2.06mmol), carbon
Sour potassium (0.28 g, 2.06mmol) and potassium iodide (0.1g, 1.01mmol) are added into DMA (6ml) liquid, which exists, and 50
6h is reacted at DEG C, 10ml water is then added, then extracted with ethyl acetate (20ml × 3), is merged organic phase, anhydrous sodium sulfate is dry
Dry, concentrate carries out post separation (eluant, eluent: DCM/MeOH (v/v)=20:1), obtains white solid 0.4g.
The synthesis of step 2 compound T-4
0.4g compound 34 is dissolved in 40mL methanol, prepared using following condition (instrument: SFC-80 (Thar,
Waters);Chiral column: OJ-H 20*250mm, 10um (Daicel);Column temperature: 35 DEG C;Mobility: CO2/ methanol (contains 0.2% ammonia
Methanol)=87/13;Flow velocity: 80g/min;Column pressure: 100bar;Detection wavelength: 214nm;Circulation time: 6.0min;Each sample introduction
Volume: 1.0mL), four isomers are obtained, chiral analysis (instrument: Agilent 1200 is carried out using following condition;Chiral column:
IG 4.6×250mm,5um (Decial);Column temperature: 25 DEG C;Mobile phase: n-hexane (contains 0.1 diethylamine): ethyl alcohol (contains 0.1%
Diethylamine)=60:40;Flow velocity: 1.0mL/min;Detection wavelength: 214nm;Sample volume: 15uL), wherein retention time=
33.77min is compound T-4, white solid 80mg.LC-MS:m/z=576.3 (M+1)+,UV 214;1H NMR
(500MHz,CDCl3)δ/ppm:7.14-7.08(m,4H), 7.03-7.00(m,1H),6.89-6.87(m,1H),6.83-
6.81 (m, 1H), 5.99 (s, 2H), 5.87 (d, J=7.5Hz, 1H), 5.27 (dd, J=14.0 Hz, J=2.5Hz, 1H),
4.63 (dd, J=14.0Hz, J=2.5Hz, 1H), 4.51 (dd, J=10.0Hz, J=2.5Hz, 1H), 4.06 (d, J=14.0
Hz, 1H), 3.93 (dd, J=11.0Hz, J=3.0Hz, 1H), 3.76 (dd, J=11.0Hz, J=3.0Hz, 1H), 3.55 (t, J
=10.5Hz, 1H), 3.46-3.41 (m, 1H), 2.96-2.91 (m, 1H)
Biological activity test.
(1) metabolic stability is evaluated
Microsomal assay: people's hepatomicrosome (Human liver microsome, HLM): 0.5mg/mL, Xenotech;Greatly
Rat hepatic microsome (Rat liver microsome, RLM): 0.5mg/mL, Xenotech;Coenzyme (NADPH/NADH): 1mM,
Sigma Life Science;Magnesium chloride: 5mM, 100mM phosphate buffer (pH 7.4).
The preparation of stock solution: precision weighs the powder of a certain amount of embodiment compound and reference substance compound, is used in combination
DMSO is dissolved to 5mM respectively.
The preparation of phosphate buffer (100mM, pH=7.4): take the 150mL prepared in advance 0.5M potassium dihydrogen phosphate and
The 0.5M dipotassium hydrogen phosphate solution of 700mL mixes, then adjusts mixed liquor pH value to 7.4 with 0.5M dipotassium hydrogen phosphate solution, uses
It is preceding to dilute 5 times with ultrapure water, magnesium chloride is added, phosphate buffer (100mM) is obtained, wherein potassium phosphate containing 100mM, 3.3mM
Magnesium chloride, pH 7.4.
It prepares NADPH regenerative system solution and (contains 6.5mM NADP, 16.5mM G-6-P, 3U/mL G-6-P D, 3.3mM
Magnesium chloride), using it is preposition in it is wet on ice.
Prepare terminate liquid: the acetonitrile containing 50ng/mL Propranolol Hydrochloride and 200ng/mL orinase (internal standard) is molten
Liquid.It takes 25057.5 μ L phosphate buffers (pH7.4) into 50mL centrifuge tube, is separately added into 812.5 μ L people's hepatomicrosomes, mix
It is even, obtain the hepatomicrosome dilution that protein concentration is 0.625mg/mL.Take 25057.5 μ L phosphate buffers (pH7.4) extremely
In 50mL centrifuge tube, 812.5 μ L SD rat liver microsomes are separately added into, are mixed, the liver that protein concentration is 0.625mg/mL is obtained
Microsome dilution.
The incubation of sample: being diluted to 0.25mM for the stock solution of respective compound with the aqueous solution containing 70% acetonitrile respectively,
It is spare as working solution.It takes people's hepatomicrosome of 398 μ L or rat liver microsomes dilution that 96 holes are added respectively to be incubated in plate
(N=2), it is separately added into the working solution of 2 μ L 0.25mM, mixes.
The measurement of metabolic stability: the terminate liquid of 300 μ L pre-cooling is added in every hole of 96 hole deep-well plates, is placed in ice
On, as termination plate.96 holes are incubated for plate and NADPH regenerative system is placed in 37 DEG C of water baths, 100 revs/min of concussions are incubated in advance
5min.80 μ L Incubating Solutions addition termination plate is taken out from the every hole of plate is incubated for, mixes, supplements 20 μ L NADPH regenerative system solution, make
For 0min sample.Again to the NADPH regenerative system solution for being incubated for 80 μ L of the every hole addition of plate, starting reaction starts timing.Correspondingization
The reaction density for closing object is 1 μM, protein concentration 0.5mg/mL.When reacting 10,30,90min, 100 μ L is respectively taken to react
Liquid is added in termination plate, and vortex 3min terminates reaction.Termination plate is centrifuged 10min under the conditions of 5000 × g, 4 DEG C.Take 100 μ L
Supernatant is mixed to being previously added in 96 orifice plates of 100 μ L distilled water, carries out sample analysis using LC-MS/MS.
Data analysis: by LC-MS/MS system detection respective compound and interior target peak area, calculate compound with it is interior
Mark peak area ratio.Slope is measured by the natural logrithm of the percentage of compound surplus and time mapping, and according to following
Formula calculates t1/2And CLint, wherein V/M is equal to 1/ protein concentration.
To the compounds of this invention and its not deuterated compound is test compare simultaneously, evaluates it in people and rat liver microsomes
The metabolic stability of body.Using without deuterated compound Baloxavir marboxil as reference substance.In people and rats'liver
In microsomal assay, by compareing with without deuterated compound Baloxavir marboxil, the compounds of this invention can be bright
It is aobvious to improve metabolic stability.The hepatomicrosome experimental result of representative embodiment compound is as shown in table 1 below.
Table 1:
(2) pharmacokinetics in rats is tested
6 male Sprague-Dawley rats, 7-8 week old, weight about 210g are divided into 2 groups, every group 3, through vein or
The compound (oral 10mg/kg) of oral single dosage, compares its pharmacokinetic difference.
Rat is raised using standard feed, gives water.Test is fasted for first 16 hours.Drug is sub- with PEG400 and diformazan
Sulfone dissolution.Eye socket blood sampling, the time point of blood sampling are 0.25 hour, 0.5 hour, 1 hour, 2 hours, 4 0.083 hour after administration
Hour, 6 hours, 8 hours, 12 hours and 24 hours.
Rat sucks of short duration anesthesia after ether, and eye socket acquires 300 μ L sample of blood in test tube.There is 30 μ L, 1% heparinate in test tube
Solution.Before use, test tube is stayed overnight in 60 DEG C of drying.After the last one time point blood specimen collection completion, rat etherization
After put to death.
It after blood specimen collection, leniently overturns test tube at least 5 times, is placed on ice after guaranteeing mixing sufficiently immediately.Blood sample is 4
DEG C 5000rpm is centrifuged 5 minutes, and blood plasma is separated with red blood cell.100 μ L blood plasma are sucked out to clean plastic centrifuge with pipettor
Guan Zhong indicates title and the time point of compound.Blood plasma is stored in -80 DEG C before being analyzed.Blood plasma is measured with LC-MS/MS
The concentration of middle the compounds of this invention.Pharmacokinetic parameter is based on every animal blood concentration in different time points into calculating.
Experiment, which shows the compounds of this invention in animal body, has better pharmacokinetic property, therefore has more preferable
Pharmacodynamics and therapeutic effect.
(3) external anti-influenza virus activity Strain: influenza virus A/WSN/33 (H1N1), cell: MDCK;
Application cell lesion (CPE) method tests the antiviral activity of test-compound infected by influenza strain, while measuring thin
Cellular toxicity.Compound tests 8 concentration, duplicate hole.Cell viability is detected using CCK-8 reagent.Compound initial concentration is
500nM, final concentration of 0.229nM, 3 times of gradient dilutions.
Mdck cell is inoculated in 384 orifice plates with the density in 2000/hole, in 37 DEG C, 5%CO2Overnight incubation.Second day
Compound and virus is added, cell (virus-free infection) and virus-infected controls are set.Cell culture DMSO is final concentration of
0.5%.Cell is in 37 DEG C, 5%CO2Culture 5 days to virus control wells cytopathy variability reach 80-95%.Cytotoxicity experiment with
Antiviral breeding is identical, but virus-free infection.Cell viability is detected using CCK-8 reagent, initial data is disease-resistant for compound
Cytotoxic activity and cytotoxicity calculate.Using GraphPad Prism software analysis of compounds dose-effect curve and calculate EC50With
CC50Value.
To the compounds of this invention and its not deuterated compound is test compare simultaneously, evaluates its antiviral activity and cell
Toxicity.The result shows that the compounds of this invention shows higher compared with without deuterated compound Baloxavir marboxil
CPE inhibitory effect, therefore the compounds of this invention can more efficiently inhibit cap dependence endonuclease in influenza virus
(CDE), to play the role of suppressing virus replication.The antiviral activity of representative embodiment compound and the knot of cytotoxicity
Fruit is as shown in table 2 below.
Table 2
Embodiment compound | EC50(nM) | CC50(nM) |
Baloxavir marboxil | 10.11 | >500 |
T-1 | 10.05 | >500 |
T-2 | 3.54 | >500 |
T-3 | 6.11 | >500 |
T-4 | 5.94 | >500 |
The above content is a further detailed description of the present invention in conjunction with specific preferred embodiments, and it cannot be said that
Specific implementation of the invention is only limited to these instructions.For those of ordinary skill in the art to which the present invention belongs, exist
Under the premise of not departing from present inventive concept, a number of simple deductions or replacements can also be made, all shall be regarded as belonging to of the invention
Protection scope.
Claims (10)
1. a kind of formula (I) compound or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, water
Close object or solvated compounds:
Wherein,
P is selected from H or-C (R11R12)OC(O)OC(R13R14R15);
Y1、Y2、Y3、Y4、Y5、Y6、Y7And Y8It is each independently selected from hydrogen or deuterium;
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14And R15It is each independently selected from hydrogen or deuterium;
Additional conditions are that above compound at least contains a D-atom.
2. compound described in claim 1, wherein R7、R8、R9、R10、R11、R12、R13、R14And R15At least one of be deuterium.
3. compound of any of claims 1 or 2, wherein R3It is deuterium.
4. the described in any item compounds of claim 1-3, wherein R7、R8、R9And R10It is deuterium.
5. the described in any item compounds of claim 1-4, wherein R11And R12It is deuterium.
6. the described in any item compounds of claim 1-5, wherein R13、R14And R15It is deuterium.
7. compound described in claim 1 is selected from following formula: compound:
Or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds.
8. a kind of pharmaceutical composition contains pharmaceutically acceptable excipient and of any of claims 1-7ization
Close object or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvated compounds.
9. compound of any of claims 1-7 or its tautomer, stereoisomer, prodrug, crystal form, pharmacy
Upper acceptable salt, hydrate or solvated compounds or pharmaceutical composition according to any one of claims 8 be used to prepare treatment and/
Or prevention and the purposes in the drug of the disease as caused by the virus with cap dependence endonuclease.
10. purposes as claimed in claim 9, wherein the disease as caused by the virus with cap dependence endonuclease is selected from
Flu-A, influenza B or influenza C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018108413886 | 2018-07-27 | ||
CN201810841388 | 2018-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110317211A true CN110317211A (en) | 2019-10-11 |
CN110317211B CN110317211B (en) | 2022-05-13 |
Family
ID=68124543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910675084.1A Active CN110317211B (en) | 2018-07-27 | 2019-07-25 | Substituted polycyclic pyridone compound and prodrug thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110317211B (en) |
WO (1) | WO2020020267A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111057070A (en) * | 2019-10-30 | 2020-04-24 | 浙江工业大学 | Synthesis method of baroxavir key intermediate |
CN111233891A (en) * | 2020-03-04 | 2020-06-05 | 江苏柯菲平医药股份有限公司 | Fused ring pyridone derivative and preparation method and application thereof |
CN111808069A (en) * | 2020-07-21 | 2020-10-23 | 中国药科大学 | Preparation method of baroxavir key intermediate and intermediate thereof |
CN111825699A (en) * | 2019-04-15 | 2020-10-27 | 上海复星星泰医药科技有限公司 | Sulfur-containing heterocyclic compounds and process for producing the same |
CN112409379A (en) * | 2020-09-28 | 2021-02-26 | 长沙晶易医药科技有限公司 | Deuterated dihydrodibenzothiazepine compounds and pharmaceutical compositions containing the same |
CN112707862A (en) * | 2019-10-24 | 2021-04-27 | 广东东阳光药业有限公司 | Preparation method of polycyclic pyridone compound |
WO2021093860A1 (en) * | 2019-11-13 | 2021-05-20 | 南京知和医药科技有限公司 | Substituted bis-tricyclic compound, and pharmaceutical composition and use thereof |
CN112898312A (en) * | 2021-01-29 | 2021-06-04 | 湖南南新制药股份有限公司 | Fused polycyclic pyridone derivative and application thereof |
CN113527119A (en) * | 2021-06-30 | 2021-10-22 | 和鼎(南京)医药技术有限公司 | Preparation method of Barosavir intermediate |
CN113549088A (en) * | 2021-08-25 | 2021-10-26 | 北京理工大学 | Preparation method of baroxavir key intermediate |
CN113717199A (en) * | 2021-08-13 | 2021-11-30 | 北京北朋科技有限公司 | Deuterated derivative of baroxavir and application of deuterated derivative in anti-influenza virus |
CN116284048A (en) * | 2023-05-18 | 2023-06-23 | 长沙晶易医药科技股份有限公司 | Compound and preparation method, pharmaceutical composition and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108440564B (en) * | 2018-04-11 | 2019-08-06 | 安帝康(无锡)生物科技有限公司 | Substituted polycyclic carbamoylpyridone derivative and its prodrug |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2812363A1 (en) * | 2010-09-24 | 2012-03-29 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
JP6267397B1 (en) * | 2016-08-10 | 2018-01-24 | 塩野義製薬株式会社 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrugs thereof |
CN107709321A (en) * | 2015-04-28 | 2018-02-16 | 盐野义制药株式会社 | The polycyclic Pyridione derivatives and its prodrug being substituted |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109503625A (en) * | 2018-01-19 | 2019-03-22 | 赵蕾 | A kind of polycyclic pyridines ketone compound and its pharmaceutical composition and purposes |
CN108440564B (en) * | 2018-04-11 | 2019-08-06 | 安帝康(无锡)生物科技有限公司 | Substituted polycyclic carbamoylpyridone derivative and its prodrug |
-
2019
- 2019-07-25 WO PCT/CN2019/097614 patent/WO2020020267A1/en active Application Filing
- 2019-07-25 CN CN201910675084.1A patent/CN110317211B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2812363A1 (en) * | 2010-09-24 | 2012-03-29 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
AU2011307087A1 (en) * | 2010-09-24 | 2013-04-11 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
CN107709321A (en) * | 2015-04-28 | 2018-02-16 | 盐野义制药株式会社 | The polycyclic Pyridione derivatives and its prodrug being substituted |
JP6267397B1 (en) * | 2016-08-10 | 2018-01-24 | 塩野義製薬株式会社 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrugs thereof |
WO2018030463A1 (en) * | 2016-08-10 | 2018-02-15 | 塩野義製薬株式会社 | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
Non-Patent Citations (1)
Title |
---|
王世真: "《分子核医学》", 31 May 2001 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111825699B (en) * | 2019-04-15 | 2023-02-21 | 上海复星星泰医药科技有限公司 | Sulfur-containing heterocyclic compounds and process for producing the same |
CN111825699A (en) * | 2019-04-15 | 2020-10-27 | 上海复星星泰医药科技有限公司 | Sulfur-containing heterocyclic compounds and process for producing the same |
CN112707862B (en) * | 2019-10-24 | 2022-09-27 | 广东东阳光药业有限公司 | Preparation method of polycyclic pyridone compound |
CN112707862A (en) * | 2019-10-24 | 2021-04-27 | 广东东阳光药业有限公司 | Preparation method of polycyclic pyridone compound |
CN111057070A (en) * | 2019-10-30 | 2020-04-24 | 浙江工业大学 | Synthesis method of baroxavir key intermediate |
WO2021093860A1 (en) * | 2019-11-13 | 2021-05-20 | 南京知和医药科技有限公司 | Substituted bis-tricyclic compound, and pharmaceutical composition and use thereof |
CN111233891A (en) * | 2020-03-04 | 2020-06-05 | 江苏柯菲平医药股份有限公司 | Fused ring pyridone derivative and preparation method and application thereof |
CN111233891B (en) * | 2020-03-04 | 2021-05-04 | 江苏柯菲平医药股份有限公司 | Fused ring pyridone derivative and preparation method and application thereof |
CN111808069B (en) * | 2020-07-21 | 2022-05-17 | 中国药科大学 | Preparation method of baroxavir key intermediate and intermediate thereof |
CN111808069A (en) * | 2020-07-21 | 2020-10-23 | 中国药科大学 | Preparation method of baroxavir key intermediate and intermediate thereof |
WO2022063016A1 (en) * | 2020-09-28 | 2022-03-31 | 长沙晶易医药科技有限公司 | Deuterated dihydrodibenzothiepine compound, and pharmaceutical composition containing same |
CN112409379B (en) * | 2020-09-28 | 2023-07-28 | 长沙晶易医药科技股份有限公司 | Deuterated dihydrodibenzothiazepine compound and pharmaceutical composition containing same |
CN112409379A (en) * | 2020-09-28 | 2021-02-26 | 长沙晶易医药科技有限公司 | Deuterated dihydrodibenzothiazepine compounds and pharmaceutical compositions containing the same |
CN112898312A (en) * | 2021-01-29 | 2021-06-04 | 湖南南新制药股份有限公司 | Fused polycyclic pyridone derivative and application thereof |
CN112898312B (en) * | 2021-01-29 | 2021-11-12 | 湖南南新制药股份有限公司 | Fused polycyclic pyridone derivative and application thereof |
CN113527119A (en) * | 2021-06-30 | 2021-10-22 | 和鼎(南京)医药技术有限公司 | Preparation method of Barosavir intermediate |
CN113717199B (en) * | 2021-08-13 | 2022-04-01 | 北京北朋科技有限公司 | Deuterated derivative of baroxavir and application of deuterated derivative in anti-influenza virus |
CN113717199A (en) * | 2021-08-13 | 2021-11-30 | 北京北朋科技有限公司 | Deuterated derivative of baroxavir and application of deuterated derivative in anti-influenza virus |
CN113549088B (en) * | 2021-08-25 | 2022-10-04 | 北京理工大学 | Preparation method of baroxavir key intermediate |
CN113549088A (en) * | 2021-08-25 | 2021-10-26 | 北京理工大学 | Preparation method of baroxavir key intermediate |
CN116284048A (en) * | 2023-05-18 | 2023-06-23 | 长沙晶易医药科技股份有限公司 | Compound and preparation method, pharmaceutical composition and application thereof |
CN116284048B (en) * | 2023-05-18 | 2023-08-15 | 长沙晶易医药科技股份有限公司 | Compound and preparation method, pharmaceutical composition and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2020020267A1 (en) | 2020-01-30 |
CN110317211B (en) | 2022-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110317211A (en) | Substituted polycyclic pyridone compound and prodrug thereof | |
JP6804790B1 (en) | N4-Hydroxycytidines and derivatives and their related antiviral uses | |
RU2770096C1 (en) | Polycyclic derivatives of carbamoyl pyridone, pharmaceutical compositions and application thereof | |
CN113015726B (en) | Ketone amide compound and preparation method, pharmaceutical composition and application thereof | |
WO2022143473A1 (en) | Nucleoside compound and use thereof | |
US9771361B2 (en) | Inhibitors of influenza viruses replication | |
US10155746B2 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
ES2747633T3 (en) | Combination of KMO 6- (3-chloro-4-cyclopropoxyphenyl) pyrimidine-4-carboxylic acid inhibitor with an antiviral agent for the treatment of HIV related neurological disorders | |
US20230192622A1 (en) | Anti-sars-cov-2 drug | |
CN111909174B (en) | Crystal form of pyridone derivative, preparation method and application | |
WO2023185763A1 (en) | Peptidomimetic compound, and preparation method, pharmaceutical composition and use therefor | |
EA033921B1 (en) | Sialic acid derivatives and use thereof in treating influenza viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |